Virbac : Declaration of the number of shares and voting rights 05/2026
Virbac : Declaration of the number of shares and voting rights 04/2026
Virbac : Public release of Virbac Annual Report at 31 December 2025.
Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms
Virbac : Declaration of the number of shares and voting rights 03/2026
Virbac SA (VRBCF) Q4 2025 Earnings Call Transcript
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025
Virbac: 2025 annual results
Virbac : Declaration of the number of shares and voting rights 02/2026
Virbac : Declaration of the number of shares and voting rights 01/2026
Virbac : Declaration of the number of shares and voting rights 11/2025
VIRBAC Announces Third Quarter 2025 Sales
Virbac SA (VRBCF) Q2 2025 Earnings Call Transcript
Virbac: 2025 Half-year results
Virbac : Public release of the Half-Year Financial Report at 30 June 2025.
Virbac : Half-yearly financial report 2025
Virbac:: Paul Martingell's compensation terms
Virbac: in the first half of 2025, revenue recorded solid growth of +5.6% at constant exchange rates and scope of consolidation
VIRBAC: Paul Martingell is appointed chief executive officer of Virbac, effective September 1, 2025
Virbac : Public release of Virbac Annual Report at 31 December 2024
Virbac: In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope
Pet Dental Health Market Forecast Report 2025-2030, with Petdentist, Virbac, Animal Dental Clinic, iM3, The Happy Jack Co., Pet Kare Clinic, Felican Pet Hospital, Ruddington Vets, Pets'n'Vets and more
Virbac SA (VRBCF) Q4 2024 Earnings Call Transcript
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2024
Virbac: 2024 Annual results
Virbac: Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)
Virbac : Declaration of the number of shares and voti
Virbac: Strong revenue growth as of the end of September at +12.6% and +8.6% at constant exchange rates and scope. 2024 targets maintained.
Virbac SA (VRBCF) Q2 2024 Earnings Call Transcript